文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

口服剪接调节剂 branaplam 治疗亨廷顿病:一项 2 期随机对照试验

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
PubMed 文献 · Nat Med · 2026-01-05

VIBRANT-HD 是一项在亨廷顿病(HD)患者中开展的随机 2b 期研究,评估口服 HTT mRNA 剪接调节剂 branaplam,并包含非人灵长类临床前数据。初始队列 21 例接受 branaplam 56 mg 每周治疗者中 18 例(85.7%)出现至少一种周围神经病体征或症状,该安全性信号及剂量建模结果触发研究提前终止;branaplam 成为首个降低 HD 患者脑脊液突变型 HTT 水平的剪接调节剂。

要点

  • 初始队列 21 例接受 branaplam 56 mg 每周治疗者中 18 例(85.7%)出现至少一种周围神经病体征或症状。
  • 该安全性信号及剂量建模结果触发 VIBRANT-HD 提前终止。
  • branaplam 是首个降低 HD 患者脑脊液突变型 HTT 水平的剪接调节剂。

核心结论

  • branaplam 是首个在 HD 患者脑脊液中降低突变型 HTT 水平的剪接调节剂。
  • 初始队列中 85.7%(18/21)接受 branaplam 56 mg 每周治疗者出现至少一种周围神经病体征或症状,该安全性信号及剂量建模结果触发 VIBRANT-HD 提前终止。

研究设计与样本

  • VIBRANT-HD 是一项在 HD 患者中开展的随机 2b 期研究,评估口服 HTT mRNA 剪接调节剂 branaplam,并包含非人灵长类临床前数据。
  • 研究采用由临床前数据指导的创新设计,包括靶向安全性监测措施(如血神经丝轻链测量、神经传导研究)和阶梯式队列以早期捕捉潜在神经毒性效应。
  • 初始队列 21 例接受 branaplam 56 mg 每周治疗。

主要发现

  • 初始队列 21 例接受 branaplam 56 mg 每周治疗者中,18 例(85.7%)出现至少一种周围神经病体征或症状。
  • 主要结局为脑脊液突变型 HTT 水平较安慰剂的降低,以描述性方式总结。
  • 多数参与者中观察到的神经丝轻链水平升高在停药后逆转。

局限性

  • 主要结局以描述性方式总结。
  • 研究因安全性信号提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lowering mutant huntingtin (HTT) gene products is a promising approach for slowing the progression of Huntington's disease (HD), a monogenic neurodegenerative disease caused by an expansion mutation in the HTT gene (NCBI Gene ID: 3064). Branaplam, an orally available HTT messenger RNA splicing modulator, reduces HTT protein levels in vitro and in animal models, and is the first splicing modulator to be evaluated in individuals with HD. Here we present the design and results of VIBRANT-HD, a randomized phase 2b study of branaplam in HD, along with preclinical findings in nonhuman primates. VIBRANT-HD utilized an innovative study design informed by our preclinical data, including targeted safety monitoring measures (for example, neurofilament light chain measurements in blood, nerve conduction studies), and staggered cohorts to capture potential neurotoxic effects early. Of the 21 participants in the initial cohort receiving branaplam 56 mg weekly, 18 (85.7%) showed at least one sign or symptom of peripheral neuropathy. This safety signal, along with dose-modeling results triggered the early termination of VIBRANT-HD. The primary outcome, a decrease in cerebrospinal fluid mutant HTT levels versus placebo, was summarized descriptively, making branaplam the first splicing modulator to lower mutant HTT levels in the cerebrospinal fluid of individuals with HD. Increased neurofilament light chain levels observed in most participants reversed after treatment discontinuation. ClinicalTrials.gov identifier: NCT05111249.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Borowsky B, Ramos H, Caputo A, et al. Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial. Nat Med. 2026. PMID: 41491108. doi:10.1038/s41591-025-04117-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。